Accelerating Drug Discovery with Co-Scientist Agents
Tempus AI Launches Lens Agentic AI for Cancer Research
The new platform uses co-scientist agents and multimodal data to accelerate oncology drug development.
A scientist in a laboratory looking at a large digital screen displaying biological data visualizations and molecular structures with the Tempus Lens logo.
Photo: Avantgarde News
Tempus AI announced the launch of its next-generation Lens platform on May 31, 2026 [1][2]. This pioneering agentic AI system is designed to accelerate drug development and oncology research [1][3]. The platform integrates over a decade of real-world multimodal data to provide researchers with deeper insights into patient outcomes [1].
The updated Lens features AI "co-scientist" agents that allow researchers to propose complex biological hypotheses in plain language [1]. These agents then provide automated, code-backed analysis plans [1][3]. This technology aims to transform how scientists interact with large datasets to find new cancer treatments [1].
Editorial notes
Transparency note
AI assisted drafting. Human edited and reviewed.
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
Reviewed for sourcing quality and editorial consistency.
Sources
- 1.↗
businesswire.com
https://www.businesswire.com/news/home/20260531652876/en/Tempus-Unveils-the-Next-Generation-of-Lens-Expanding-its-Agentic-AI-Platform-for-Oncology-Drug-Development
- 2.↗
lasvegassun.com
https://lasvegassun.com/news/2026/may/31/tempus-unveils-the-next-generation-of-lens-expandi/
- 3.↗
intellectia.ai
https://intellectia.ai/news/stock/tempus-launches-nextgen-ai-platform-lens-to-accelerate-drug-development
Related stories
View all
Topics
About the author
Avantgarde News Desk covers accelerating drug discovery with co-scientist agents and editorial analysis for Avantgarde News.